ReviewHuman vaccines2009
Vaccines against tularemia.
Review in Human vaccines, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Dillapiole Dampens the Expression of the Major Virulence Genes ofMolecules (Basel, Switzerland) · 2025Article
- Development, Strategies, and Challenges for Tularemia Vaccine.Current microbiology · 2024Review
- Tularemia - a re-emerging disease with growing concern.The veterinary quarterly · 2023Article
- Comparative evaluation of protective immunity againstFrontiers in cellular and infection microbiology · 2023Article
- Structural and biophysical properties of FopA, a major outer membrane protein of Francisella tularensis.PloS one · 2022Article
- Deletion Mutants ofPathogens (Basel, Switzerland) · 2021Article
- Tularemia: a re-emerging tick-borne infectious disease.Folia microbiologica · 2021Review
- Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies toProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Deletion of the Major Facilitator Superfamily TransporterInfection and immunity · 2018Article
- An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.Frontiers in microbiology · 2018Article
- Article
- Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.Clinical and vaccine immunology : CVI · 2017Article
- Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.Pathogens and disease · 2016Article
- Antioxidant Defenses of Francisella tularensis Modulate Macrophage Function and Production of Proinflammatory Cytokines.The Journal of biological chemistry · 2016Article
- Transmission-Blocking Vaccines: Focus on Anti-Vector Vaccines against Tick-Borne Diseases.Archivum immunologiae et therapiae experimentalis · 2015Review
- Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.PloS one · 2015Article
- TolC-dependent modulation of host cell death by the Francisella tularensis live vaccine strain.Infection and immunity · 2014Article
- Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.Clinical and vaccine immunology : CVI · 2014Article
- Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.PloS one · 2014Article
- Disruption of Francisella tularensis Schu S4 iglI, iglJ, and pdpC genes results in attenuation for growth in human macrophages and in vivo virulence in mice and reveals a unique phenotype for pdpC.Infection and immunity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Francisella tularensis is a Category A select agent for which vaccine and countermeasure development are a priority. In the past eight years, renewed interest in this pathogen has led to the generation of an enormous amount of new data on both the pathogen itself and its interaction with host cells. This information has fostered the development of various vaccine candidates including acellular subunit, killed whole cell and live attenuated. This review summarizes the progress and promise of these various candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.